StoneX reiterates Buy on CoreCivic stock, $45 target maintained

CoreCivic reported Q2 2026 adjusted EPS of $0.38 versus $0.33 consensus and revenue of $684.9 million versus $615.79 million expected. The company generated approximately $1.6 billion in net proceeds from four DHS facility sales and initiated a $500 million accelerated share repurchase, with roughly $255.8 million remaining under its repurchase authorization. StoneX maintained its Buy rating and $45 price target, citing rising ICE detentions and DHS plans to acquire at least 10 purpose-built facilities, although the shares trade near their 52-week high and may be overvalued.

Analysis

CXW’s capital return is mechanically supportive near term, but the more important valuation question is whether proceeds from owned real estate are being recycled into higher-return contracted management cash flows or merely distributed while the recurring revenue base shrinks. Asset monetization lowers leverage and equity risk, yet it can reduce future operating optionality if government ownership ultimately internalizes economics that formerly accrued to private operators. The market is likely assigning a premium to the balance-sheet reset before evidence exists on replacement contract margins.

GEO is the cleaner second-order read-through: a government preference for owned facilities potentially creates a monetization channel for both operators, but asset-specific negotiations make it dangerous to extrapolate CXW’s outcome directly. The differentiated variable is which company has facilities that meet agency location, design, and security requirements, not aggregate detention demand. A sustained increase in utilization should improve fixed-cost absorption across both names over the next 1-3 quarters, but contract renewal terms—not population data—will determine incremental EBITDA conversion.

The immediate risk is that accelerated repurchases pull forward demand rather than create durable per-share value; once the program is completed, CXW needs contract awards, improved pricing, or additional asset sales to support further multiple expansion. Over 6-18 months, the thesis is vulnerable to a policy reversal, litigation-driven detention constraints, or government procurement delays that leave capacity underutilized. Falsification signals are lower facility occupancy, contract renewals at weaker economics, or management guiding to reduced recurring EBITDA despite lower interest expense.

Key Decisions for Investors

• Do not chase CXW at recent highs solely on the buyback. Initiate only on an 8-10% pullback or following disclosure that divested facilities retain long-duration management contracts; target 15-20% upside over 6-12 months versus an 8% stop if recurring EBITDA guidance weakens.
• Establish a small, catalyst-driven long GEO watch position only if it announces a comparable facility monetization or major ICE/DHS award. The opportunity is peer valuation catch-up, but absent an asset-specific catalyst the read-through is too weak for a full position.
• For relative-value books, consider long GEO / short CXW only if CXW materially outperforms further without a corresponding increase in recurring contract backlog. Target a 10-15% spread compression over 3-6 months; cover if CXW secures replacement management revenue or GEO reports unfavorable renewal pricing.
• Monitor quarterly net debt, recurring EBITDA excluding sale gains, occupancy, and contract duration rather than headline EPS. A decline in leverage paired with stable recurring EBITDA supports holding CXW; sale-driven EPS growth without that stability is a trim signal.